Correction to: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial (Nature Medicine, (2025), 31, 8, (2806-2814), 10.1038/s41591-025-03738-z)

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-025-03738-z, published online 31 May 2025. In the version of the article initially published, in the final sentence of the “Primary endpoint” paragraph, “72.2% for Arm C (N = 193)” should have read “72.2% for Arm C (N = 194)”. In the “OS” paragraph, “one-sided P = 0.6791; Fig. 4b” should have read “one-sided P = 0.6043; Fig. 4b”. In the first sentence of the “Safety” paragraph, “Arm B (N = 349)” should have read “Arm B (N = 348)”. In the “Stratified hazard ratio (95%CI)” column of Fig. 4b, “(0.64–1.88)” should have read “(0.64–1.79)”. In the Table 2 legend, “Included are TRAEs that occurred in at least 5% of the patients…” should have read “Included are TRAEs that occurred in at least 7.5% of the patients…”. In Extended Data Figs. 1 and 2, “Stratified hazard ratio” should have read “Unstratified hazard ratio”. These corrections have now been made to the HTML and PDF versions of the article.